These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

368 related items for PubMed ID: 12568409

  • 1. Relation of androgen receptor gene polymorphism to bone mineral density and fracture risk in early postmenopausal women during a 5-year randomized hormone replacement therapy trial.
    Salmén T, Heikkinen AM, Mahonen A, Kröger H, Komulainen M, Pallonen H, Saarikoski S, Honkanen R, Mäenpää PH.
    J Bone Miner Res; 2003 Feb; 18(2):319-24. PubMed ID: 12568409
    [Abstract] [Full Text] [Related]

  • 2. The protective effect of hormone-replacement therapy on fracture risk is modulated by estrogen receptor alpha genotype in early postmenopausal women.
    Salmén T, Heikkinen AM, Mahonen A, Kröger H, Komulainen M, Saarikoski S, Honkanen R, Mäenpää PH.
    J Bone Miner Res; 2000 Dec; 15(12):2479-86. PubMed ID: 11127213
    [Abstract] [Full Text] [Related]

  • 3. Relation of aromatase gene polymorphism and hormone replacement therapy to serum estradiol levels, bone mineral density, and fracture risk in early postmenopausal women.
    Salmen T, Heikkinen AM, Mahonen A, Kröger H, Komulainen M, Pallonen H, Saarikoski S, Honkanen R, Mäenpää PH.
    Ann Med; 2003 Dec; 35(4):282-8. PubMed ID: 12846271
    [Abstract] [Full Text] [Related]

  • 4. Early postmenopausal bone loss is associated with PvuII estrogen receptor gene polymorphism in Finnish women: effect of hormone replacement therapy.
    Salmén T, Heikkinen AM, Mahonen A, Kröger H, Komulainen M, Saarikoski S, Honkanen R, Mäenpää PH.
    J Bone Miner Res; 2000 Feb; 15(2):315-21. PubMed ID: 10703934
    [Abstract] [Full Text] [Related]

  • 5. Leucine7 to proline7 polymorphism in prepro-NPY gene and femoral neck bone mineral density in postmenopausal women.
    Heikkinen AM, Niskanen LK, Salmi JA, Koulu M, Pesonen U, Uusitupa MI, Komulainen MH, Tuppurainen MT, Kröger H, Jurvelin J, Saarikoski S.
    Bone; 2004 Sep; 35(3):589-94. PubMed ID: 15336593
    [Abstract] [Full Text] [Related]

  • 6. Polymorphisms in the CYP19 and AR genes--relation to bone mass and longitudinal bone changes in postmenopausal women with or without hormone replacement therapy: The Danish Osteoporosis Prevention Study.
    Tofteng CL, Kindmark A, Brändström H, Abrahamsen B, Petersen S, Stiger F, Stilgren LS, Jensen JE, Vestergaard P, Langdahl BL, Mosekilde L, Danish Osteoporosis Prevention Study.
    Calcif Tissue Int; 2004 Jan; 74(1):25-34. PubMed ID: 14517714
    [Abstract] [Full Text] [Related]

  • 7. Association between androgen receptor gene polymorphism and bone density in older women using hormone replacement therapy.
    Retornaz F, Paris F, Lumbroso S, Audran F, Tigoulet F, Michelon C, Jeandel C, Sultan C, Blain H.
    Maturitas; 2006 Nov 20; 55(4):325-33. PubMed ID: 16759824
    [Abstract] [Full Text] [Related]

  • 8. COL1A1 Sp1 polymorphism predicts perimenopausal and early postmenopausal spinal bone loss.
    MacDonald HM, McGuigan FA, New SA, Campbell MK, Golden MH, Ralston SH, Reid DM.
    J Bone Miner Res; 2001 Sep 20; 16(9):1634-41. PubMed ID: 11547832
    [Abstract] [Full Text] [Related]

  • 9. [The influence of hormonal replacement therapy on bone density in postmenopausal women depending on polymorphism of vitamin D receptor (VDR) and estrogen receptor (ER) genes].
    Brodowska A.
    Ann Acad Med Stetin; 2003 Sep 20; 49():111-30. PubMed ID: 15552843
    [Abstract] [Full Text] [Related]

  • 10. Biochemical bone markers and bone mineral density during postmenopausal hormone replacement therapy with and without vitamin D3: a prospective, controlled, randomized study.
    Heikkinen AM, Parviainen M, Niskanen L, Komulainen M, Tuppurainen MT, Kröger H, Saarikoski S.
    J Clin Endocrinol Metab; 1997 Aug 20; 82(8):2476-82. PubMed ID: 9253321
    [Abstract] [Full Text] [Related]

  • 11. Does vitamin D strengthen the increase in femoral neck BMD in osteoporotic women treated with estrogen?
    Tuppurainen MT, Komulainen M, Kröger H, Honkanen R, Jurvelin J, Puntila E, Heikkinen AM, Alhava E, Saarikoski S.
    Osteoporos Int; 1998 Aug 20; 8(1):32-8. PubMed ID: 9692075
    [Abstract] [Full Text] [Related]

  • 12. The effects of hormone replacement therapy and resistance training on spine bone mineral density in early postmenopausal women.
    Maddalozzo GF, Widrick JJ, Cardinal BJ, Winters-Stone KM, Hoffman MA, Snow CM.
    Bone; 2007 May 20; 40(5):1244-51. PubMed ID: 17291843
    [Abstract] [Full Text] [Related]

  • 13. A CAG repeat polymorphism in the androgen receptor gene is associated with reduced bone mass and increased risk of osteoporotic fractures.
    Langdahl BL, Stenkjaer L, Carstens M, Tofteng CL, Eriksen EF.
    Calcif Tissue Int; 2003 Sep 20; 73(3):237-43. PubMed ID: 14667136
    [Abstract] [Full Text] [Related]

  • 14. A common methylenetetrahydrofolate reductase (C677T) polymorphism is associated with low bone mineral density and increased fracture incidence after menopause: longitudinal data from the Danish osteoporosis prevention study.
    Abrahamsen B, Madsen JS, Tofteng CL, Stilgren L, Bladbjerg EM, Kristensen SR, Brixen K, Mosekilde L.
    J Bone Miner Res; 2003 Apr 20; 18(4):723-9. PubMed ID: 12674333
    [Abstract] [Full Text] [Related]

  • 15. Recency and duration of postmenopausal hormone therapy: effects on bone mineral density and fracture risk in the National Osteoporosis Risk Assessment (NORA) study.
    Barrett-Connor E, Wehren LE, Siris ES, Miller P, Chen YT, Abbott TA, Berger ML, Santora AC, Sherwood LM.
    Menopause; 2003 Apr 20; 10(5):412-9. PubMed ID: 14501602
    [Abstract] [Full Text] [Related]

  • 16. Prevention of femoral and lumbar bone loss with hormone replacement therapy and vitamin D3 in early postmenopausal women: a population-based 5-year randomized trial.
    Komulainen M, Kröger H, Tuppurainen MT, Heikkinen AM, Alhava E, Honkanen R, Jurvelin J, Saarikoski S.
    J Clin Endocrinol Metab; 1999 Feb 20; 84(2):546-52. PubMed ID: 10022414
    [Abstract] [Full Text] [Related]

  • 17. Vitamin D receptor gene polymorphisms and the risk of fractures in older women. For the Study of Osteoporotic Fractures Research Group.
    Ensrud KE, Stone K, Cauley JA, White C, Zmuda JM, Nguyen TV, Eisman JA, Cummings SR.
    J Bone Miner Res; 1999 Oct 20; 14(10):1637-45. PubMed ID: 10491209
    [Abstract] [Full Text] [Related]

  • 18. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal.
    Cosman F, Nieves J, Woelfert L, Formica C, Gordon S, Shen V, Lindsay R.
    J Bone Miner Res; 2001 May 20; 16(5):925-31. PubMed ID: 11341338
    [Abstract] [Full Text] [Related]

  • 19. Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study.
    Bagger YZ, Tankó LB, Alexandersen P, Hansen HB, Møllgaard A, Ravn P, Qvist P, Kanis JA, Christiansen C.
    Bone; 2004 Apr 20; 34(4):728-35. PubMed ID: 15050905
    [Abstract] [Full Text] [Related]

  • 20. Two polymorphisms in the vitamin D receptor gene--association with bone mass and 5-year change in bone mass with or without hormone-replacement therapy in postmenopausal women: the Danish Osteoporosis Prevention Study.
    Tofteng CL, Jensen JE, Abrahamsen B, Odum L, Brot C.
    J Bone Miner Res; 2002 Aug 20; 17(8):1535-44. PubMed ID: 12162507
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.